Relationship Between Red Cell Distribution Width (RDW) and HbA1C in Patients With Type 2 Diabetes Mellitus After Glycemic Control
Recruiting · NCT06067399 · Observational (researchers observe without assigning treatment) · Lead sponsor: New Valley University
View the official record on ClinicalTrials.gov →Interventions studied
Glycated hemoglobin (HbA1C)Lipid profileRDW
What this trial is about
Diabetes mellitus (DM) is an epidemic disease, with approximately 463 million persons diagnosed with it. Of those, 90% are patients with type 2 DM (T2DM). Some estimates indicate that 700 million cases of DM will be reported in 2045. T2DM develops due to insulin resistance, leading to reduced insulin secretion. DM has a number of associated complications, such as nephropathy, neuropathy, and cardiovascular disease.
Who can take part
Age range
40 Years and older
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Patients diagnosed to have Uncontrolled type 2 diabetes mellitus (HbA1C more than 7%)
Exclusion criteria
- Patients diagnosed to have type 1 diabetes.
- Patients are diagnosed to have secondary diabetes.
- Clinical states associated with increased RDW:
- Anemia (Female Hb less than 12, Male Hb less than 13) either due to hemolysis, or in response to ineffective red cell production, which can be caused by deficiencies in iron, vitamin B12 or folate.
- After blood transfusions
- Pregnancy, thrombotic thrombocytopenic purpura and inflammatory bowel disease.
Where it is running
1 location listed.
- New Valley University- Faculty of Medicine - Al Khārjah, Egypt